[go: up one dir, main page]

FI20100329A0 - Immunomodulatory adjuvant therapy - Google Patents

Immunomodulatory adjuvant therapy

Info

Publication number
FI20100329A0
FI20100329A0 FI20100329A FI20100329A FI20100329A0 FI 20100329 A0 FI20100329 A0 FI 20100329A0 FI 20100329 A FI20100329 A FI 20100329A FI 20100329 A FI20100329 A FI 20100329A FI 20100329 A0 FI20100329 A0 FI 20100329A0
Authority
FI
Finland
Prior art keywords
adjuvant therapy
immunomodulatory adjuvant
immunomodulatory
alitretinoin
employing
Prior art date
Application number
FI20100329A
Other languages
Finnish (fi)
Swedish (sv)
Inventor
Antti Alitalo
Original Assignee
Antti Alitalo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antti Alitalo filed Critical Antti Alitalo
Priority to FI20100329A priority Critical patent/FI20100329A0/en
Publication of FI20100329A0 publication Critical patent/FI20100329A0/en
Priority to PCT/FI2011/050820 priority patent/WO2012038605A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to employing alitretinoin as a viral therapy enhancing adjuvant.
FI20100329A 2010-09-24 2010-09-24 Immunomodulatory adjuvant therapy FI20100329A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20100329A FI20100329A0 (en) 2010-09-24 2010-09-24 Immunomodulatory adjuvant therapy
PCT/FI2011/050820 WO2012038605A1 (en) 2010-09-24 2011-09-23 Viral therapy enhancing adjuvant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20100329A FI20100329A0 (en) 2010-09-24 2010-09-24 Immunomodulatory adjuvant therapy

Publications (1)

Publication Number Publication Date
FI20100329A0 true FI20100329A0 (en) 2010-09-24

Family

ID=42829651

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20100329A FI20100329A0 (en) 2010-09-24 2010-09-24 Immunomodulatory adjuvant therapy

Country Status (2)

Country Link
FI (1) FI20100329A0 (en)
WO (1) WO2012038605A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
AU2007215328A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy

Also Published As

Publication number Publication date
WO2012038605A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
JOP20180102B1 (en) Pharmaceutical compound
UY34780A (en) VIRAL VECTORS FOR THE TREATMENT OF RETINIAN DYSTROPHY
EP2800530A4 (en) THERAPY TRANSDUCER BY HISTOTRIPSY
EA201291154A1 (en) CHOICE OF DOSES OF SYNTHETIC NANOSATORS WITH ADJUVANTS
DK3403995T3 (en) High-solubility iron hexacyanides
UY34582A (en) ANTI-CXCR3 ANTIBODIES
BR112014033077A2 (en) vaccine combination.
UY34074A (en) HIGHLY CONCENTRATED OLOPATADINE OPHTHALMIC COMPOSITION
BR112013021779A2 (en) muc1-based glycolipopeptide vaccine with adjuvant.
CR20150084A (en) 2-OXO-2,3-DIHYDRO-INDOLES
FR2988733B1 (en) RECOMBINANT MICROORGANISM
CL2011002403S1 (en) Solar luminaire
CY1118539T1 (en) RECOMBINANT MYBACTERIUM AS A VACCINE
FI20116335L (en) Improving the efficiency of peracids
HK1213880A1 (en) Cyclic amines
FI20110109A0 (en) Cyclic PSD pressing procedure
UY34286A (en) IMPROVED VACCINE DIAGNOSIS
EP2929893A4 (en) ADJUVANT FOR MUCOSAL MEMBRANE VACCINE
MX335957B (en) Fireproof ceramic impact absorber.
TR201007106A1 (en) Cefpodoxime proxetil formulations.
UY34501A (en) ? FACTOR PURIFICATION PROCEDURE VIII ?.
IN2012DE02272A (en)
GB201120634D0 (en) Adjuvant polypeptide
FI20100329A0 (en) Immunomodulatory adjuvant therapy
IT1401158B1 (en) COOKTOP

Legal Events

Date Code Title Description
FD Application lapsed